NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $0.48 +0.02 (+5.00%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$0.46 -0.02 (-3.43%) As of 06/15/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jasper Therapeutics Stock (NASDAQ:JSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.45▼$0.5250-Day Range$0.46▼$1.0652-Week Range$0.42▼$7.19Volume509,062 shsAverage Volume614,004 shsMarket Capitalization$13.45 millionP/E RatioN/ADividend YieldN/APrice Target$13.14Consensus RatingHold Company Overview Jasper Therapeutics, Inc. (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine. Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation. In parallel, Jasper is advancing JN-6000, an extended-release formulation of tacrolimus aimed at reducing the toxicity and dosing complexities associated with conventional immunosuppressive regimens. The company is also investigating JN-403, a small-molecule agent intended to prevent and treat vaso-occlusive crises in sickle cell disease. Since its founding, Jasper Therapeutics has established collaborations with leading academic institutions and biotechnology partners to support its clinical programs and expand its platform capabilities. The company is headquartered in Tarrytown, New York, and maintains research activities in key U.S. biotech hubs. Jasper’s leadership team brings together expertise in translational medicine, clinical development, and regulatory affairs to guide its efforts from early-stage discovery through pivotal studies. With a strategic focus on leveraging immunological insights to design targeted therapies, Jasper Therapeutics aims to deliver novel treatment options for patients experiencing life-threatening disorders. Its ongoing clinical trials and preclinical initiatives reflect a commitment to advancing scientific innovation in areas where current therapeutic choices are limited.AI Generated. May Contain Errors. Read More Jasper Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreJSPR MarketRank™: Jasper Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 294th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingJasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialJasper Therapeutics has a consensus price target of $13.14, representing about 2,635.2% upside from its current price of $0.48.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Jasper Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($1.81) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Jasper Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.41% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 9.51.Change versus previous monthShort interest in Jasper Therapeutics has recently decreased by 9.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.94 News SentimentJasper Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jasper Therapeutics this week, compared to 5 articles on an average week.Search Interest5 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.60% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPR Stock News HeadlinesJasper Therapeutics (NASDAQ:JSPR) Trading Down 5% - Should You Sell?June 9, 2026 | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)June 2, 2026 | theglobeandmail.comFree today: My 7-point options checklistBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | Profits Run (Ad)Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueJune 1, 2026 | globenewswire.comJasper Therapeutics Announces Board Resignation and Committee ChangeMay 21, 2026 | tipranks.comJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | globenewswire.comJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | markets.businessinsider.comJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | globenewswire.comSee More Headlines JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $1.83 at the start of the year. Since then, JSPR stock has decreased by 73.7% and is now trading at $0.4805. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.08. When did Jasper Therapeutics' stock split? Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Jasper Therapeutics' major shareholders? Top institutional shareholders of Jasper Therapeutics include Renaissance Technologies LLC (0.63%) and Knott David M Jr (0.57%). Insiders that own company stock include Velan Capital Investment Manag, Judith Anne Shizuru, Ron Martell, Thomas G Wiggans, Jeetinder Singh Mahal and Svetlana Lucas. View institutional ownership trends. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jasper Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/14/2026Today6/15/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 JSPR's financial health is in the Red zone, according to TradeSmith. JSPR has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPR CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jasper Therapeutics$13.14 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+2,635.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-613.51% Return on Assets-162.52% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book3.20Miscellaneous Outstanding Shares28,000,000Free Float26,709,000Market Cap$13.45 million OptionableOptionable Beta3.01 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:JSPR) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThe number nobody's bragging aboutSPCX - the largest IPO in history - was predicted to open at $175. It opened at $150. Insiders bought in at a ...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
